Prostate Cancer
TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)
- Details
ClinicalTrials.gov ID:
NCT02975934
Diagnosis Type:
NA
USOR Number:
- Address
7777 Forest Lane, Suite D400
Dallas, TX 75230
P: (972) 566-6647